Cellarity applies single-cell technologies and proprietary deep learning models to identify cellular drivers of disease and design drugs against the cellular signature. The company links biology and chemistry with high-dimensional transcriptomic data to create medicines that target whole-cell dysfunction rather than single molecular targets. Founded by Flagship Pioneering in 2017 and based in Somerville, Mass., Cellarity has developed capabilities to unravel complex disease biology and reveal new biology for drug creation. The company reports compounds validated in vitro and in vivo, including in higher species, and has ongoing programs in metabolic disease, hematology, and immuno-oncology. Cellarity plans to use recent financing proceeds to grow its talent base, strengthen its platform, and advance its pipeline toward the clinic. To date the company has raised $274 million in total funding. Cellarity is a Cambridge, Mass.-based life sciences company founded in 2017 within Flagship Labs. It is developing a new method of drug discovery that targets the cell rather than a single molecular target. The company combines system and network biology, high-resolution data and machine learning to unlock treatments across multiple therapeutic areas. Cellarity is led by Fabrice Chouraqui, who serves as CEO of Cellarity and is a CEO-Partner at Flagship Pioneering. In February 2021 the company raised $123M in a Series B financing. The funds will support its platform and drug discovery efforts across its stated therapeutic focus areas.

Total raised

$244M

Funding rounds

2

Latest round

Series C

Latest activity

Oct 2022